Melanie J. Davies

90.4k total citations · 46 hit papers
1.0k papers, 57.9k citations indexed

About

Melanie J. Davies is a scholar working on Endocrinology, Diabetes and Metabolism, Physiology and Epidemiology. According to data from OpenAlex, Melanie J. Davies has authored 1.0k papers receiving a total of 57.9k indexed citations (citations by other indexed papers that have themselves been cited), including 598 papers in Endocrinology, Diabetes and Metabolism, 233 papers in Physiology and 165 papers in Epidemiology. Recurrent topics in Melanie J. Davies's work include Diabetes Treatment and Management (320 papers), Diabetes Management and Research (273 papers) and Diabetes Management and Education (176 papers). Melanie J. Davies is often cited by papers focused on Diabetes Treatment and Management (320 papers), Diabetes Management and Research (273 papers) and Diabetes Management and Education (176 papers). Melanie J. Davies collaborates with scholars based in United Kingdom, United States and Australia. Melanie J. Davies's co-authors include Kamlesh Khunti, Thomas Yates, Laura J. Gray, Sudesna Chatterjee, Francesco Zaccardi, John B. Buse, Charlotte L. Edwardson, Chantal Mathieu, David R. Webb and Peter Rossing and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Melanie J. Davies

971 papers receiving 56.1k citations

Hit Papers

Management of Hyperglycemia in Ty... 2006 2026 2012 2019 2018 2021 2017 2012 2018 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2018 2.6k citations Melanie J. Davies et al. Diabetes Care profile →
  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity
    2021 2.5k citations John Wilding, Rachel L. Batterham et al. New England Journal of Medicine profile →
  3. Type 2 diabetes
    2017 1.8k citations Kamlesh Khunti, Melanie J. Davies et al. profile →
  4. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis
    2012 1.3k citations Emma G. Wilmot, Charlotte L. Edwardson et al. profile →
  5. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2018 1.1k citations Melanie J. Davies et al. profile →
  6. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
    2021 1.1k citations Juan P. Frías, Melanie J. Davies et al. New England Journal of Medicine profile →
  7. The prevalence of co‐morbid depression in adults with Type 2 diabetes: a systematic review and meta‐analysis
    2006 954 citations Saima Ali, Margaret Stone et al. Diabetic Medicine profile →
  8. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2022 947 citations Melanie J. Davies et al. Diabetes Care profile →
  9. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2019 834 citations Melanie J. Davies et al. Diabetes Care profile →
  10. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
    2021 806 citations Melanie J. Davies, Julio Rosenstock et al. profile →
  11. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
    2015 793 citations Melanie J. Davies, Robert F. Kushner et al. JAMA profile →
  12. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis
    2020 688 citations Kamlesh Khunti, Melanie J. Davies et al. profile →
  13. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
    2021 646 citations Thomas A. Wadden, Timothy S. Bailey et al. JAMA profile →
  14. Type 2 diabetes
    2022 612 citations David R. Webb, Melanie J. Davies et al. profile →
  15. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial
    2008 571 citations Melanie J. Davies, Helen Dallosso et al. profile →
  16. Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis
    2010 550 citations Laura J. Gray, Kamlesh Khunti et al. profile →
  17. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2022 532 citations Melanie J. Davies et al. profile →
  18. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
    2007 529 citations Melanie J. Davies et al. New England Journal of Medicine profile →
  19. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
    2022 515 citations John Wilding, Rachel L. Batterham et al. profile →
  20. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
    2009 502 citations Melanie J. Davies et al. New England Journal of Medicine profile →
  21. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes
    2006 497 citations Melanie J. Davies, Tadeusz Dereziński et al. Diabetes Care profile →
  22. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
    2010 486 citations Timothy S. Bailey, Melanie J. Davies et al. profile →
  23. Clinical Inertia in People With Type 2 Diabetes
    2013 482 citations Kamlesh Khunti, Melanie J. Davies et al. Diabetes Care profile →
  24. Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations
    2014 420 citations Danielle H. Bodicoat, Thomas Yates et al. Diabetes Care profile →
  25. The effects of high‐intensity interval training on glucose regulation and insulin resistance: a meta‐analysis
    2015 409 citations Thomas Yates, Laura J. Gray et al. profile →
  26. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective
    2015 397 citations Francesco Zaccardi, David R. Webb et al. profile →
  27. Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals
    2020 385 citations Clare Gillies, Francesco Zaccardi et al. Diabetes & Metabolic Syndrome Clinical Research & Reviews profile →
  28. Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis
    2016 383 citations Francesco Zaccardi, David R. Webb et al. profile →
  29. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention
    2019 353 citations Kamlesh Khunti, Melanie J. Davies et al. profile →
  30. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2019 352 citations Melanie J. Davies et al. profile →
  31. Considerations when using the activPAL monitor in field-based research with adult populations
    2016 352 citations Charlotte L. Edwardson, Danielle H. Bodicoat et al. profile →
  32. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
    2017 347 citations Melanie J. Davies, Julio Rosenstock et al. JAMA profile →
  33. The prevalence of diabetes‐specific emotional distress in people with Type 2 diabetes: a systematic review and meta‐analysis
    2017 328 citations Melanie J. Davies, Kamlesh Khunti et al. Diabetic Medicine profile →
  34. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
    2017 305 citations Melanie J. Davies et al. New England Journal of Medicine profile →
  35. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea
    2019 302 citations Julio Rosenstock, Melanie J. Davies et al. JAMA profile →
  36. Physical activity, multimorbidity, and life expectancy: a UK Biobank longitudinal study
    2019 227 citations Kamlesh Khunti, Francesco Zaccardi et al. profile →
  37. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
    2023 193 citations Juan P. Frías, Ildiko Lingvay et al. profile →
  38. What is the pipeline for future medications for obesity?
    2024 161 citations Eka Melson, Dimitris Papamargaritis et al. profile →
  39. Semaglutide for the treatment of overweight and obesity: A review
    2022 130 citations Melanie J. Davies, Ildiko Lingvay et al. profile →
  40. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
    2024 123 citations Mikhail Kosiborod, Barry A. Borlaug et al. profile →
  41. Semaglutide and NT-proBNP in Obesity-Related HFpEF
    2024 47 citations Mark C. Petrie, Barry A. Borlaug et al. Journal of the American College of Cardiology profile →
  42. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials
    2024 43 citations Barry A. Borlaug, Javed Butler et al. profile →
  43. Inflammation in Obesity-Related HFpEF
    2024 41 citations Subodh Verma, Mark C. Petrie et al. Journal of the American College of Cardiology profile →
  44. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
    2025 37 citations W. Timothy Garvey, Melanie J. Davies et al. New England Journal of Medicine profile →
  45. The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review
    2025 19 citations Melanie J. Davies, Dimitris Papamargaritis et al. profile →
  46. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
    2025 19 citations Melanie J. Davies, Ildiko Lingvay et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melanie J. Davies United Kingdom 105 32.1k 12.5k 10.9k 10.0k 7.3k 1.0k 57.9k
Jonathan E. Shaw Australia 97 34.4k 1.1× 17.0k 1.4× 12.6k 1.2× 9.1k 0.9× 14.0k 1.9× 571 82.7k
Jaakko Tuomilehto Finland 114 23.2k 0.7× 14.1k 1.1× 7.0k 0.6× 7.2k 0.7× 9.1k 1.3× 776 61.5k
David R. Matthews United Kingdom 81 44.0k 1.4× 13.9k 1.1× 18.3k 1.7× 16.3k 1.6× 12.8k 1.8× 272 75.4k
Kamlesh Khunti United Kingdom 109 24.3k 0.8× 9.3k 0.7× 6.1k 0.6× 6.2k 0.6× 8.6k 1.2× 1.2k 54.7k
Naveed Sattar United Kingdom 132 22.9k 0.7× 11.5k 0.9× 9.2k 0.8× 12.7k 1.3× 13.9k 1.9× 1.2k 73.0k
Robert H. Eckel United States 82 22.0k 0.7× 16.8k 1.3× 8.7k 0.8× 8.2k 0.8× 14.4k 2.0× 242 65.3k
Steven M. Haffner United States 125 33.2k 1.0× 11.4k 0.9× 11.2k 1.0× 11.1k 1.1× 14.5k 2.0× 518 62.2k
Hertzel C. Gerstein Canada 94 26.6k 0.8× 7.6k 0.6× 8.8k 0.8× 8.1k 0.8× 5.6k 0.8× 505 51.2k
Bernard Zinman Canada 106 44.5k 1.4× 7.3k 0.6× 18.6k 1.7× 18.0k 1.8× 5.3k 0.7× 652 63.6k
Julie E. Buring United States 128 12.5k 0.4× 9.9k 0.8× 6.9k 0.6× 10.9k 1.1× 10.8k 1.5× 602 66.5k

Countries citing papers authored by Melanie J. Davies

Since Specialization
Citations

This map shows the geographic impact of Melanie J. Davies's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melanie J. Davies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melanie J. Davies more than expected).

Fields of papers citing papers by Melanie J. Davies

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melanie J. Davies. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melanie J. Davies. The network helps show where Melanie J. Davies may publish in the future.

Co-authorship network of co-authors of Melanie J. Davies

This figure shows the co-authorship network connecting the top 25 collaborators of Melanie J. Davies. A scholar is included among the top collaborators of Melanie J. Davies based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melanie J. Davies. Melanie J. Davies is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Davies, Melanie J., Carl May, Shivani Misra, et al.. (2025). Using normalisation process theory to understand implementation of effective early-onset type 2 diabetes treatment and care within England: a qualitative study. BMC Health Services Research. 25(1). 422–422. 2 indexed citations
3.
Barker, Mary M., Jack A. Sargeant, Dimitris Papamargaritis, et al.. (2025). Burden of vascular risk factors by age, sex, ethnicity and deprivation in young adults with and without newly diagnosed type 2 diabetes. Diabetes Research and Clinical Practice. 220. 112002–112002. 2 indexed citations
4.
Rizzi, Alessandro, David E. Kloecker, Dario Pitocco, et al.. (2024). Effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on time to outcome in type 2 diabetes cardiorenal outcome trials. Diabetes & Metabolic Syndrome Clinical Research & Reviews. 18(2). 102945–102945.
5.
Verma, Subodh, Javed Butler, Barry A. Borlaug, et al.. (2024). Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 84(17). 1603–1614. 17 indexed citations
6.
Barker, Mary M., et al.. (2024). Age at onset of type 2 diabetes and prevalence of vascular disease and heart failure: Systematic review and dose-response meta-analysis. Journal of Diabetes and its Complications. 38(10). 108849–108849. 1 indexed citations
7.
Shabnam, Sharmin, Clare Gillies, Melanie J. Davies, et al.. (2023). Factors associated with therapeutic inertia in individuals with type 2 diabetes mellitus started on basal insulin. Diabetes Research and Clinical Practice. 203. 110888–110888. 3 indexed citations
8.
9.
Zaccardi, Francesco, Frank Dudbridge, Paddy C. Dempsey, et al.. (2022). Self-reported walking pace, polygenic risk scores and risk of coronary artery disease in UK biobank. Nutrition Metabolism and Cardiovascular Diseases. 32(11). 2630–2637. 8 indexed citations
10.
Dempsey, Paddy C., Crispin Musicha, Alex V. Rowlands, et al.. (2022). Investigation of a UK biobank cohort reveals causal associations of self-reported walking pace with telomere length. Communications Biology. 5(1). 381–381. 28 indexed citations
11.
Wadden, Thomas A., Timothy S. Bailey, Liana K. Billings, et al.. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 325(14). 1403–1403. 646 indexed citations breakdown →
12.
Wilding, John, Rachel L. Batterham, Salvatore Calanna, et al.. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 384(11). 989–1002. 2476 indexed citations breakdown →
13.
Gulsin, Gaurav S., Emer M. Brady, Anna-Marie Marsh, et al.. (2021). Clinical associations with stage B heart failure in adults with type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism. 12. 2425399424–2425399424. 4 indexed citations
14.
Henson, Joseph, Alex V. Rowlands, Jack A. Sargeant, et al.. (2020). Device‐measured physical activity and its association with physical function in adults with type 2 diabetes mellitus. Diabetic Medicine. 38(6). e14393–e14393. 16 indexed citations
15.
16.
Rowlands, Alex V., Nathan P. Dawkins, Benjamin D. Maylor, et al.. (2019). Enhancing the value of accelerometer-assessed physical activity: meaningful visual comparisons of data-driven translational accelerometer metrics. Sports Medicine - Open. 5(1). 47–47. 56 indexed citations
17.
18.
Davies, Melanie J., et al.. (2008). Reduced Weight Gain with Insulin Detemir Compared to NPH Insulin Is Not Explained by a Reduction in Hypoglycemia. Diabetes Technology & Therapeutics. 10(4). 273–277. 38 indexed citations
19.
Ali, Saima, Margaret Stone, Jaime Peters, Melanie J. Davies, & Kamlesh Khunti. (2006). The prevalence of co‐morbid depression in adults with Type 2 diabetes: a systematic review and meta‐analysis. Diabetic Medicine. 23(11). 1165–1173. 954 indexed citations breakdown →
20.
ZuWallack, Richard, et al.. (1996). Alterations in total and regional body composition in patients with moderate to severe obstructive lung disease.. PubMed. 51(6). 507–9. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan E. Shaw Breakdown of academic impact, for papers by Jaakko Tuomilehto Breakdown of academic impact, for papers by David R. Matthews Breakdown of academic impact, for papers by Kamlesh Khunti Breakdown of academic impact, for papers by Naveed Sattar Breakdown of academic impact, for papers by Robert H. Eckel Breakdown of academic impact, for papers by Steven M. Haffner Breakdown of academic impact, for papers by Hertzel C. Gerstein Breakdown of academic impact, for papers by Bernard Zinman Breakdown of academic impact, for papers by Julie E. Buring
Rankless by CCL
2026